Biotech 2050 Podcast cover image

David Meeker, CEO of Rhythm Pharmaceuticals, on Rare Disease Breakthroughs & Biotech’s Future

Biotech 2050 Podcast

00:00

Transformative Innovations in Rare Disease Treatment

This chapter explores Genzyme's historical development and its groundbreaking approval of Gaucher disease treatment in 1991. It highlights the innovative enzyme replacement therapies and competitive dynamics in the biotech sector that reshaped the treatment of rare diseases.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app